Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis

Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis

Little is known about the efficacy and safety of the anti-interleukin 5 monoclonal antibody mepolizumab (MPZ) in patients with eosinophilic granulomatosis with polyangiitis (EGPA) in real-life. We thus evaluated disease activity, damage and disease-related complications in 14 patients with EGPA rece...

Full description

Bibliographic Details
Main Authors: Giuseppe A. Ramirez, Adriana Cariddi, Silvia Noviello, Corrado Campochiaro, Valentina Canti, Luca Moroni, Mona-Rita Yacoub, Elena M. Baldissera, Enrica P. Bozzolo, Lorenzo Dagna
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Clinical Immunology Communications
Subjects:
Eosinophilic granulomatosis with polyangiitis
Mepolizumab
Asthma
Corticosteroids
Infections
Online Access:http://www.sciencedirect.com/science/article/pii/S2772613422000026

Internet

http://www.sciencedirect.com/science/article/pii/S2772613422000026

Similar Items